Zacks Investment Research
25 Mar 2026, 17:01 UTC · 33w ago
Coherus Oncology (CHRS) Upgraded to Buy: Here's What You Should Know
Verdict
Source says Upgrade to Buy. We score CHRS +1.00.
Score confirms the headline.
- Headline says
Upgrade to Buy
Rating stated in the headline
- Expected · CHRS
+1.00strongly bullish
−1 bearish0bullish +1More positive than 98% of ticker scores this week
- Actual

Search tags




